SR9011 vs Stenabolic

SR9011 wins for: Slightly cleaner receptor selectivity (REV-ERBα/β), less notoriety (so less prone to bunk sourcing), and potentially broader effects on metabolic genes per rodent data.

Stenabolic wins for: Far more robust practical documentation, easier sourcing, established protocols and stack guides, and a strong reputation in the endurance/recomp community. Dosing protocols, stacks, and user reports are all more dialed in.

Pick SR9011 if:

• The research goal is focused on mechanistic REV-ERBα/β activation with minimal off-target noise.
• Sourcing challenges with Stenabolic are an issue and verified SR9011 is available.
• The protocol aims to probe circadian, sleep, or hepatic-metabolic effects beyond endurance.
• The intention is to cross-compare multiple Scripps agonists in a metabolic screen.
• There's interest in minimizing name-recognition for regulatory or compliance reasons.

Pick Stenabolic if:

• Community protocols, anecdotal logs, and stack ideas are critical to the research plan.
• Cardio endurance, recomp, or lipid profile is the primary outcome of interest.
• There's a need to work from a well-understood dosage schedule (20–40mg/day in split doses).
• Sourcing legitimate compound is easier—SR9009 is much more widely available.
• The protocol involves stacking with GW-501516/Cardarine or cutting-phase peptides.